Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Multicenter Pilot Trial of Intrathecal Liposomal Cytarabine Combined with FAB Chemoimmunotherapy with Reduced Doxorubicin in CAYA with Mature De-Novo B-NHL

Anthony N. Audino, Stanton Goldman, Matthew J. Barth, Jessica Hochberg, Ana C. Xavier, Bruce Shiramizu, Qiuhu Shi, Lauren Harrison, Jackie Basso, Javier Oesterheld, Kenneth Matthew Heym, Richard A. Drachtman, Paul Harker-Murray, Sherrie L. Perkins, Rodney R. Miles, Mitchell S. Cairo

Blood (2023) 142 (Supplement 1): 1727.

https://doi.org/10.1182/blood-2023-181756

Published: 2023

Journal Articles

Targeted Immunotherapy and Checkpoint Blockade in Children, Adolescents, and Young Adults with Lymphoma: Radical Hodgkin Cohort

Kayleigh Klose, Jessica Hochberg, Jaclyn Basso, Ana C. Xavier, Matthew J. Barth, Rodney R. Miles, Samir Kahwash, Stephan D. Voss, Suzanne Braniecki, Chitti Moorthy, Saro Armenian, Matthew J. Ehrhardt, Megan Lim, Lauren Harrison, Arvind Budhram, Ariel Stonberg, Stanton Goldman, Mitchell S. Cairo

Blood (2023) 142 (Supplement 1): 3083.

https://doi.org/10.1182/blood-2023-186691

Published: 2023

Journal Articles

Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL)

Jessica C. Hochberg, MD, Stanton Goldman, MD, Matthew J. Barth, MD, Qiuhu Shi, PhD, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Jackie Basso, Yaya Chu, PhD, Humayun Islam, Perry Gerard, MD MBA, FACR, Javier Oesterheld, MD, Kenneth Matthew Heym, MD, Ivan I. Kirov, MD, Richard A. Drachtman, MD, Paul Harker-Murray, MD PhD, Sherrie L. Perkins, MD PhD, Rodney R. Miles, MD PhD, Bruce Shiramizu, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-139464

Published: 2020

Journal Articles

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Anthony N. Audino, MD, Matthew J. Barth, MD, Aradhana Tiwari, PhD, Dina Edani, MS, Janet Ayello, MS, MT(ASCP), Lauren Harrison, RN, MSN, Erin Morris, RN, BSN, Jessica C. Hochberg, MD, Stanton Goldman, MD, Christian Klein, PhD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 3963.

https://doi.org/10.1182/blood-2019-128580

Published: 2019

Journal Articles

BRAF-V600E in Peripheral Mononuclear Cells and Microglia-like Brain Cells Suggest Hematopoietic Origin of Langerhans Cell Histiocytosis-Associated Neurodegeneration

Blood (2017) 130 (Supplement 1): 2930.

https://doi.org/10.1182/blood.V130.Suppl_1.2930.2930

Published: 2017

Journal Articles

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Timmy O'Connell, MS, Lauren Harrison, RN, MSN, Carmella van de Ven, MA, Matthew J. Barth, MD, Rodney R. Miles, MD PhD, Paul J. Galardy, MD, Stanton Goldman, MD, Megan S Lim, MD PhD, Michelle L. Hermiston, MD PhD, Linda McAllister-Lucas, MDPhD, Lisa Giulino-Roth, MD, Sherrie L. Perkins, MD PhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 5117.

https://doi.org/10.1182/blood.V126.23.5117.5117

Published: 2015

Journal Articles

Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Lauren Harrison, RN, MSN, Carmella van de Ven, MA, Matthew J. Barth, MD, Rodney R. Miles, MD PhD, Paul J. Galardy, MD, Stanton Goldman, MD, Megan S Lim, MD PhD, Michelle L. Hermiston, MD PhD, Linda McAllister-Lucas, MDPhD, Lisa Giulino-Roth, MD, Sherrie L. Perkins, MD PhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 4852.

https://doi.org/10.1182/blood.V126.23.4852.4852

Published: 2015

Journal Articles

Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy

Mary Gerrard, Ian M. Waxman, Richard Sposto, Anne Auperin, Sherrie L. Perkins, Stanton Goldman, Lauren Harrison, Ross Pinkerton, Keith McCarthy, Martine Raphael, Catherine Patte, Mitchell S. Cairo

Blood (2013) 121 (2): 278–285.

https://doi.org/10.1182/blood-2012-04-422709

Published: 2013

Includes: Supplemental data

Journal Articles

The Efficacy of Rasburicase and Rituximab Combined with FAB Chemotherapy in Children and Adolescents with Newly Diagnosed Stage III/IV, BM+ and CNS+ Mature B-NHL: A Children's Oncology Group Report

Stanton Goldman, MD, Paul J. Galardy, MD, Lynette Smith, MS, Sherrie L. Perkins, MD, PhD, Bruce Shiramizu, MD, Thomas Gross, MD, PhD, Warren G. Sanger, PhD, Lauren Harrison, RN, MSN, Mitchell S. Cairo, MD

Blood (2011) 118 (21): 2702.

https://doi.org/10.1182/blood.V118.21.2702.2702

Published: 2011

Journal Articles

Genomic Pathways and Potential Therapeutic Targets in Pediatric Burkitt Lymphoma (PBL): A Children's Oncology Group Report

Mitchell S. Cairo, MD, Nancy Day, Ph.D., Stanton Goldman, MD, Warren G. Sanger, PhD, Lauren Harrison, RN, MSN, Megan S. Lim, MD, PhD, Rodney R. Miles, MD, PhD, Sherrie L. Perkins, MD, PhD

Blood (2011) 118 (21): 1587.

https://doi.org/10.1182/blood.V118.21.1587.1587

Published: 2011

Journal Articles

Preliminary Results of the Addition of Rasburicase to the Reduction Cycle and Rituximab to the Induction and Consolidation Cycles of FAB Group C Chemotherapy in Children and Adolescents with Advanced Stage (Bone Marrow ±CNS) Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report.

Stanton Goldman, MD, James Lynch, PhD, Lauren Harrison, RN, Thomas Gross, MD, PhD, Bruce Shiramizu, MD, Warren Sanger, PhD, Sherrie L. Perkins, MD, PhD, Mitchell S. Cairo, MD

Blood (2009) 114 (22): 104.

https://doi.org/10.1182/blood.V114.22.104.104

Published: 2009

Journal Articles

DLEU1 siRNA Gene Knockdown IN BURKITT LYMPHOMA (bl) IS ASSOCIATED with A SIGNIFICANT Decrease IN Cyclophosphamide (CY) and/or Rituximab Induced Apoptosis: Mechanism of Drug Resistance in BL.

Nancy Day, Ph.D., Janet Ayello, MS, MT, Carmella van de Ven, MA, Megan S Lim, MD, PhD, Sherrie L. Perkins, MD, PhD, Warren Sanger, PhD, Lauren Harrison, RN, Stanton Goldman, MD, Mitchell S. Cairo, MD

Blood (2009) 114 (22): 1928.

https://doi.org/10.1182/blood.V114.22.1928.1928

Published: 2009

Journal Articles

Safety, Efficacy and Rituximab Levels Following Chemoimmunotherapy (Rituximab + FAB Chemotherapy) in Children and Adolescents with Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children’s Oncology Group Report

Mitchell S. Cairo, MD, James Lynch, PhD, Lauren Harrison, RN, Carmella van de Ven, MS, Thomas Gross, MD, PhD, Bruce Shiramizu, MD, Warren Sanger, PhD, Sherrie L. Perkins, MD, PhD, Stanton Goldman, MD

Blood (2008) 112 (11): 838.

https://doi.org/10.1182/blood.V112.11.838.838

Published: 2008

NARROW

Multicenter Pilot Trial of Intrathecal Liposomal Cytarabine Combined with FAB Chemoimmunotherapy with Reduced Doxorubicin in CAYA with Mature De-Novo B-NHL

Targeted Immunotherapy and Checkpoint Blockade in Children, Adolescents, and Young Adults with Lymphoma: Radical Hodgkin Cohort

Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL)

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

BRAF-V600E in Peripheral Mononuclear Cells and Microglia-like Brain Cells Suggest Hematopoietic Origin of Langerhans Cell Histiocytosis-Associated Neurodegeneration

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL

Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL

Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy

The Efficacy of Rasburicase and Rituximab Combined with FAB Chemotherapy in Children and Adolescents with Newly Diagnosed Stage III/IV, BM+ and CNS+ Mature B-NHL: A Children's Oncology Group Report

Genomic Pathways and Potential Therapeutic Targets in Pediatric Burkitt Lymphoma (PBL): A Children's Oncology Group Report

DLEU1 siRNA Gene Knockdown IN BURKITT LYMPHOMA (bl) IS ASSOCIATED with A SIGNIFICANT Decrease IN Cyclophosphamide (CY) and/or Rituximab Induced Apoptosis: Mechanism of Drug Resistance in BL.

Safety, Efficacy and Rituximab Levels Following Chemoimmunotherapy (Rituximab + FAB Chemotherapy) in Children and Adolescents with Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children’s Oncology Group Report

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only